Trigeminal Neuralgia (Tic Douloureux) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 53 Published: March 31, 2022 Report Code: GMDGDHC22109IDB

Trigeminal neuralgia is a chronic pain condition that affects the trigeminal nerve, which carries sensation from face to brain. Symptoms include spontaneous attacks of pain or attacks triggered by things such as touching the face, chewing, speaking, and brushing teeth, pain in areas supplied by the trigeminal nerve, including the cheek, jaw, teeth, gums, lips, or less often the eye and forehead.

The Trigeminal Neuralgia (Tic Douloureux) Drugs in Development market research report provides an overview of the Trigeminal Neuralgia (Tic Douloureux) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Trigeminal Neuralgia (Tic Douloureux), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Trigeminal Neuralgia (Tic Douloureux) and features dormant and discontinued projects.

Trigeminal Neuralgia Pipeline Drugs Market Targets

The targets of the Trigeminal Neuralgia pipeline drugs market are Calcitonin Gene Related Peptide Type 1 Receptor, Metabotropic Glutamate Receptor 5, Sodium Channel Protein Type 9 Subunit Alpha, Sodium Dependent Dopamine Transporter, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Gamma-Aminobutyric Acid Receptor Subunit Alpha 6 (GABA, Peroxisome Proliferator Activated Receptor Gamma, Sodium Channel Protein Type 8 Subunit Alpha, Transient Receptor Potential Cation Channel Subfamily A Member 1, and Transient Receptor Potential Cation Channel Subfamily V Member 4.

Trigeminal Neuralgia pipeline drugs market, by targets

Trigeminal Neuralgia pipeline drugs market, by targets

For more target insights, download a free report sample

Mechanisms of Action of Trigeminal Neuralgia Pipeline Drugs Market

Some of the mechanisms of action of the Trigeminal Neuralgia pipeline drugs market are Calcitonin Gene Related Peptide Type 1 Receptor Antagonist, Metabotropic Glutamate Receptor 5 Antagonist, Sodium Dependent Dopamine Transporter Inhibitor, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Gamma-Aminobutyric Acid Receptor Subunit Alpha 6 (GABAAgonist, Peroxisome Proliferator Activated Receptor Gamma Agonist, Sodium Channel Protein Type 8 Subunit Alpha Blocker, Sodium Channel Protein Type 9 Subunit Alpha Blocker, and Sodium Channel Protein Type 9 Subunit Alpha Inhibitor.

Trigeminal Neuralgia pipeline drugs market, by mechanisms of action

Trigeminal Neuralgia pipeline drugs market, by mechanisms of action

For more mechanisms of action insights, download a free report sample

Routes of Administration in Trigeminal Neuralgia Pipeline Drugs Market

The routes of administration in the Trigeminal Neuralgia pipeline drugs market are oral, topical, intravenous, ophthalmic, subcutaneous, buccal, inhalational, intraocular, nasal, and sublingual.

Trigeminal Neuralgia pipeline drugs market, by routes of administration

Trigeminal Neuralgia pipeline drugs market, by routes of administration

For more routes of administration insights, download a free report sample

Molecule Types in Trigeminal Neuralgia Pipeline Drugs Market

The molecule types in the Trigeminal Neuralgia pipeline drugs market are small molecule, antisense oligonucleotide, gene therapy, monoclonal antibody, protein, and recombinant protein.

Trigeminal Neuralgia pipeline drugs market, by molecule types

Trigeminal Neuralgia pipeline drugs market, by molecule types

For more molecule type insights, download a free report sample

Key Trigeminal Neuralgia Pipeline Drugs Market Companies

Some of the key companies in the Trigeminal Neuralgia pipeline drugs market are Initiator Pharma AS, Noema Pharma AG, Acasti Pharma Inc, Amgen Inc, Biogen Inc, Biohaven Pharmaceutical Holding Company Ltd, Coda Biotherapeutics Inc, Hoba Therapeutics ApS, InMed Pharmaceuticals Inc, and Noveome Biotherapeutics Inc.

Trigeminal Neuralgia pipeline drugs market, by key companies

Trigeminal Neuralgia pipeline drugs market, by key companies

To know more about key companies, download a free report sample

Market report overview

Targets Calcitonin Gene Related Peptide Type 1 Receptor, Metabotropic Glutamate Receptor 5, Sodium Channel Protein Type 9 Subunit Alpha, Sodium Dependent Dopamine Transporter, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Gamma-Aminobutyric Acid Receptor Subunit Alpha 6 (GABA, Peroxisome Proliferator Activated Receptor Gamma, Sodium Channel Protein Type 8 Subunit Alpha, Transient Receptor Potential Cation Channel Subfamily A Member 1, and Transient Receptor Potential Cation Channel Subfamily V Member 4
Mechanisms of Action Calcitonin Gene Related Peptide Type 1 Receptor Antagonist, Metabotropic Glutamate Receptor 5 Antagonist, Sodium Dependent Dopamine Transporter Inhibitor, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Gamma-Aminobutyric Acid Receptor Subunit Alpha 6 (GABAAgonist, Peroxisome Proliferator Activated Receptor Gamma Agonist, Sodium Channel Protein Type 8 Subunit Alpha Blocker, Sodium Channel Protein Type 9 Subunit Alpha Blocker, and Sodium Channel Protein Type 9 Subunit Alpha Inhibitor
Routes of Administration Oral, Topical, Intravenous, Ophthalmic, Subcutaneous, Buccal, Inhalational, Intraocular, Nasal, and Sublingual
Molecule Types Small Molecule, Antisense Oligonucleotide, Gene Therapy, Monoclonal Antibody, Protein, and Recombinant Protein
Key Companies Initiator Pharma AS, Noema Pharma AG, Acasti Pharma Inc, Amgen Inc, Biogen Inc, Biohaven Pharmaceutical Holding Company Ltd, Coda Biotherapeutics Inc, Hoba Therapeutics ApS, InMed Pharmaceuticals Inc, and Noveome Biotherapeutics Inc

Scope

This report provides:

  • A snapshot of the global therapeutic landscape of Trigeminal Neuralgia (Central Nervous System).
  • Reviews of pipeline therapeutics for Trigeminal Neuralgia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
  • Reviews of key companies involved in Trigeminal Neuralgia (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • Evaluation of Trigeminal Neuralgia (Central Nervous System) targeted therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news and deals related to pipeline therapeutics for Trigeminal Neuralgia (Central Nervous System).

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Trigeminal Neuralgia (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Trigeminal Neuralgia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Players

Acasti Pharma Inc

Amgen Inc

Biogen Inc

Biohaven Pharmaceutical Holding Company Ltd

Coda Biotherapeutics Inc

Hoba Therapeutics ApS

Initiator Pharma AS

InMed Pharmaceuticals Inc

Noema Pharma AG

Noveome Biotherapeutics Inc

OliPass Corporation

Oxford Cannabinoid Technologies Ltd

Praxis Precision Medicines Inc

USA Elixiria Biotech Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Trigeminal Neuralgia (Tic Douloureux) – Overview

Trigeminal Neuralgia (Tic Douloureux) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Trigeminal Neuralgia (Tic Douloureux) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Trigeminal Neuralgia (Tic Douloureux) – Companies Involved in Therapeutics Development

Acasti Pharma Inc

Amgen Inc

Biogen Inc

Biohaven Pharmaceutical Holding Company Ltd

Coda Biotherapeutics Inc

Hoba Therapeutics ApS

Initiator Pharma AS

InMed Pharmaceuticals Inc

Noema Pharma AG

Noveome Biotherapeutics Inc

OliPass Corporation

Oxford Cannabinoid Technologies Ltd

Praxis Precision Medicines Inc

USA Elixiria Biotech Inc

Trigeminal Neuralgia (Tic Douloureux) – Drug Profiles

basimglurant – Drug Profile

Product Description

Mechanism Of Action

History of Events

DKI-561 – Drug Profile

Product Description

Mechanism Of Action

ELB-00824 – Drug Profile

Product Description

Mechanism Of Action

erenumab – Drug Profile

Product Description

Mechanism Of Action

History of Events

Gene Therapy for Trigeminal Neuralgia – Drug Profile

Product Description

Mechanism Of Action

GTX-201 – Drug Profile

Product Description

Mechanism Of Action

History of Events

HB-086 – Drug Profile

Product Description

Mechanism Of Action

INM-405 – Drug Profile

Product Description

Mechanism Of Action

IPTN-2021 – Drug Profile

Product Description

Mechanism Of Action

OCT-130401 – Drug Profile

Product Description

Mechanism Of Action

OLP-1002 – Drug Profile

Product Description

Mechanism Of Action

PRAX-562 – Drug Profile

Product Description

Mechanism Of Action

rimegepant sulfate ODT – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Block TRPV4 and TRPA1 for Pancreatitis and Trigeminal Neuralgia – Drug Profile

Product Description

Mechanism Of Action

ST-266 – Drug Profile

Product Description

Mechanism Of Action

vixotrigine – Drug Profile

Product Description

Mechanism Of Action

History of Events

Trigeminal Neuralgia (Tic Douloureux) – Dormant Projects

Trigeminal Neuralgia (Tic Douloureux) – Product Development Milestones

Featured News & Press Releases

Feb 22, 2022: Noema Pharma announces first patient dosed in Phase 2b LibraTN study of mGluR5 inhibitor NOE-101 in trigeminal neuralgia

Feb 14, 2022: Noema Pharma announces FDA Investigational New Drug Authorization for Phase 2b LibraTN study of mGluR5 inhibitor NOE-101 in trigeminal neuralgia

Oct 11, 2021: Oxford Cannabinoid Technologies targets chronic pain condition with latest formulation

Jul 03, 2019: Biohaven starts enrolment in rimegepant’s trigeminal neuralgia trial

Sep 23, 2014: Convergence Pharmaceuticals’ Novel Nav1.7 Selective Sodium Channel Blocker CNV1014802 Demonstrates Proof of Concept in Second Neuropathic Pain Study in Lumbosacral Radiculopathy

Jun 16, 2014: Convergence Pharmaceuticals’ Novel Sodium Channel Blocker CNV1014802 Shows Excellent Efficacy and Safety in Ground-breaking Phase II Trigeminal Neuralgia Study

Jul 30, 2013: Convergence Pharmaceuticals Receives Orphan-Drug Designation for Nav1.7 Blocking Pain Drug CNV1014802

Apr 23, 2013: Convergence Pharma Announces Successful Interim Data From Phase II Trigeminal Neuralgia Study

Mar 27, 2013: Convergence Pharma Reports Positive Interim Data From Phase II Trigeminal Neuralgia Study Of CNV-1014802

Mar 19, 2012: Convergence Initiates Phase II Study For CNV1014802 For Trigeminal Neuralgia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Trigeminal Neuralgia (Tic Douloureux), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Trigeminal Neuralgia (Tic Douloureux) – Pipeline by Acasti Pharma Inc, 2022

Trigeminal Neuralgia (Tic Douloureux) – Pipeline by Amgen Inc, 2022

Trigeminal Neuralgia (Tic Douloureux) – Pipeline by Biogen Inc, 2022

Trigeminal Neuralgia (Tic Douloureux) – Pipeline by Biohaven Pharmaceutical Holding Company Ltd, 2022

Trigeminal Neuralgia (Tic Douloureux) – Pipeline by Coda Biotherapeutics Inc, 2022

Trigeminal Neuralgia (Tic Douloureux) – Pipeline by Hoba Therapeutics ApS, 2022

Trigeminal Neuralgia (Tic Douloureux) – Pipeline by Initiator Pharma AS, 2022

Trigeminal Neuralgia (Tic Douloureux) – Pipeline by InMed Pharmaceuticals Inc, 2022

Trigeminal Neuralgia (Tic Douloureux) – Pipeline by Noema Pharma AG, 2022

Trigeminal Neuralgia (Tic Douloureux) – Pipeline by Noveome Biotherapeutics Inc, 2022

Trigeminal Neuralgia (Tic Douloureux) – Pipeline by OliPass Corporation, 2022

Trigeminal Neuralgia (Tic Douloureux) – Pipeline by Oxford Cannabinoid Technologies Ltd, 2022

Trigeminal Neuralgia (Tic Douloureux) – Pipeline by Praxis Precision Medicines Inc, 2022

Trigeminal Neuralgia (Tic Douloureux) – Pipeline by USA Elixiria Biotech Inc, 2022

Trigeminal Neuralgia (Tic Douloureux) – Dormant Projects, 2022

List of Figures

List of Figures

Number of Products under Development for Trigeminal Neuralgia (Tic Douloureux), 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently Asked Questions

Enquire Before Buying
$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.